I think you're confused. What I am complaining about is that it was used for out patients for sars-cov-2 infection leading to covid-19. We both agree that happened and I am saying that is bad and unprecedented usage outside of supervised hospital care.
Molnupiravir was never given except in the context of supervised hospital care for other viral diseases. And your link does not disprove that. My knowledge about Molnupiravir is not direct, but only from the research I, and others on IRC did, back in 2021. It is much harder to research this now with all the sars-cov-2 studies improperly using the drug muddying the results. But I assure you, your search will be 99% in-patient usage for other viral diseases. This usage is weird. And it was available only after paxolovid was approved.
Right, the Phase 3 MOVe-OUT trial (NCT04575597) was done in outpatients prior to approval, so to say it was never used in outpatients prior to approval is not accurate. Use in hospitalized patients may have been the focus of research with molnupiravir before the MOVe-OUT trial, but that does not prove that molnupiravir should not be used in an outpatient setting.
That's uselessly pedantic. Yes, the approved out patient usage for sar-cov-2 emergency was out patient in testing too. How could it be otherwise?
But it was never used as an out patient drug in prior studies or FDA approvals for other viral infections. I'm starting to think you aren't debating in good faith...
